A Phase 2 interventional study of surfactant airway device in RDS of Prematurity, Surfactant Protein B Deficiency and Chronic Lung Disease, sponsored by ONY. Suspended at 4 sites in United States. Open to participants aged 24 Weeks and older. Per ClinicalTrials.gov, last updated 2023-11-01.
Sponsored by ONY · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A pilot study to explore and determine feasibility and safety of the administration of surfactant through a new supraglottic device in patients from 500 to 5000 grams with RDS.
Surfactant therapy can be life-saving for newborn infants with respiratory distress due to surfactant insufficiency, also known as respiratory distress syndrome (RDS). All commercially available surfactants for clinical use are approved for administration through an endotracheal tube. Placement of an endotracheal tube, a procedure called intubation, is stressful for the infant and associated with significant adverse effects. The proposed supraglottic instillation device allows infants to benefit from surfactant therapy while avoiding the negative effects of intubation.
34 studies on the registry are indexed under Respiratory Distress Syndrome In Premature Infants; 10 are open to participants now.
This study's planned enrollment of 55 is above the median of 45 across 29 interventional studies indexed under Respiratory Distress Syndrome In Premature Infants.
Browse Respiratory Distress Syndrome In Premature Infants studies →ONY is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in this group will have Calfactant at 3ml/kg administered via the supraglottic administration device.
Combination Product: surfactant airway device
Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.
Instillation failures
Instillation failure is defined as a lack of clinical response
Time frame: First 10 minutes after surfactant instillation.
Treatment failure
"Treatment failure" defined as requiring intubation and liquid surfactant instillation with or without mechanical ventilation.
Time frame: First 3 days of life
Clinical response
Duration of oxygen therapy
Time frame: 3 days
Clinical response
duration of non-invasive respiratory therapy
Time frame: 3 days
Clinical response
number of rescue surfactant doses
Time frame: 3 days
Clinical response
incidence of pulmonary air leak
Time frame: 3 days
Clinical response
pulmonary hemorrhage
Time frame: 3 days
Clinical response
chronic lung disease
Time frame: defined as need for oxygen at 36 weeks post menstrual age
Start is estimated for Feb 2025; primary completion for Dec 2025, 10 months later.
How these figures are worked out, and which studies are left out of them.
This study is suspended, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome In Premature Infants →
ONY